ACR: Patients can restart rheumatic treatments 7-14 days after COVID-19 symptoms resolve

Patients with uncomplicated COVID-19 infections may consider restarting rheumatic disease treatments within 7 to 14 days of symptom resolution, according to updated guidelines from the American College of Rheumatology. On July 23, the ACR issued two additions to its previously released “COVID-19 Clinical Guidance for Adult Patients with Rheumatic Diseases.” The updates focus on

Read the full article here

Related Articles